Effect of calcium dobesilate combined with irbesartan therapy on proteinuria and serum inflammatory mediator levels in early diabetic nephropathy

摘要

Objective:To analyze the effect of calcium dobesilate combined with irbesartan therapy on proteinuria and serum inflammatory mediator levels in early diabetic nephropathy.Methods:A total of 74 patients with early diabetic nephropathy who received inpatient treatment in our hospital from July 2013 to July 2015 were included in the study and divided into observation group and control group (n=37) according to random number table. Control group received routine therapy, observation group received additional calcium dobesilate combined with irbesartan therapy, and then differences in proteinuria, hemorheology, renal blood flow parameters, serum inflammatory mediator levels and so on were compared between two groups.Results: Urine microalbumin, UAER value, whole blood viscosity, plasma viscosity, fibrinogen and Hct levels of observation group after treatment were lower than those of control group; color Doppler Vs max and Vd min values of observation group after treatment were higher than those of control group while PI and RI values were lower than those of control group; sICAM-1, MCP-1 and NLR values of observation group after treatment were lower than those of control group.Conclusion:Calcium dobesilate combined with irbesartan therapy can significantly inhibit the progression of early diabetic nephropathy and improve renal blood supply, and it has positive clinical significance.